Cd19-specific redirected immune cells
CA 2425862 C · Owner: City Of Hope · Inventors: Jensen, Michael C.; Raubitschek, Andrew; Forman, Stephen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Genetically engineered, CD19-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CD19, an intracellular signaling domain and a , transmembrane domain. Use of such cells for cellular immunotherapy of CD19+ malignancies and for abrogating any untoward B cell function. In one embodiment, the immune cell is a T cell and the cell surface protein is a single chain svFvFc:.zeta. receptor where scFc designates the VH and VL chains of a single chain monoclonal antibody to CD19 Fc represents at least part of , a constant region of an IgG1 and .zeta. represents the intracellular signaling domain of the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 7, 2001 and granted January 22, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 7, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 7, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.